iOnctura, an Amsterdam, the Netherlands-based clinical-stage biopharmaceutical company, raised EUR80M in Series B funding.
The round was led by Syncona, with participation from the European Innovation Council Fund as well as existing investors M Ventures, Inkef Capital, VI Partners, Schroders Capital and 3B Future Health Fund.
The company intends to use the funds to accelerate the development of lead assetĀ roginolisib for treatment of uveal melanoma and a number of other oncology indications. iOnctura plans to commence trials in other cancer indications, including non-small cell lung cancer and primary myelofibrosis, later in 2024.
Led by CEO Catherine Pickering, iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is an allosteric modulator of PI3KĪ“ and cambritaxestat is an autotaxin inhibitor in clinical development to treat cancer.
iOnctura’s wholly owned Swiss subsidiary, iOnctura SA, is located inĀ Geneva, Switzerland.
Commenting on the news, Catherine Pickering said: “This financing is validation of iOnctura’s approach to developing precision cancer treatments with maximum clinical impact. These therapies have the potential to significantly prolong the healthspan of patients suffering with neglected cancer types, such as uveal melanoma. We are pleased to welcome our new investors Syncona and the EIC Fund alongside our existing strong syndicate. Their experience will be invaluable as we look to advance our pipeline and take iOnctura to its next stage of growth.”
FinSMEs
20/04/2024